Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis

Table 1

RA patient characteristics.

	Blood analysis	Sera analysis
	RA patients (𝑛=16)	Responders (𝑛=16)		Nonresponders (𝑛=16)
	Mean ± s.d.	Mean ± s.d.		Mean ± s.d.
Age (years)	59.1±3	59.8±3		57.6±15
Gender (%F)	87.5	80.8		85.7
Disease duration (years)	16±2.2	13.7±1.45		16.3±2.6
ACPA positive (%)	81.3	87.5		78.6
DMARDs failed	3.5±0.25	3.7±0.25		3.5±0.4
		M0	M3	M0	M3
Baseline DAS 28	5.4±0.25	6.2±0.2	3.7±0.2	4.8±0.3	5.2±0.3
Baseline CRP level (mg/L)	12.3±4	29.4±6	11.4±4	20.2±8	15.3±5
Baseline HAQ level	1.4±0.1	1.7±0.1	1.4±0.2	1.75±0.2	1.5±0.2

DAS 28 score: a measure of RA activity score (28 joints were evaluated); DMARDs: disease modifying antirheumatic drugs; s.d.: standard deviation; ACPA: anticitrullinated protein/peptide antibodies; CRP: C-reactive protein l; HAQ: health assessment questionnaire.